[1] SCHRADER J W.Interleukin is as interleukin does[J].J Immunol Methods,2003,276(1):1-3.
[2] COLLISON L W,WORKMAN C J,KUO T T,et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J].Nature,2007,450(7169):566-569.
[3] COLLISON L W,DELGOFFE G M,GUY C S,et al.The composition and signaling of the IL-35 receptor are unconventional[J].Nat Immunol,2012,13(3):290-299.
[4] SAWANT D V,HAMILTON K,VIGNALI D A.Interleukin-35:expanding its job profile[J].J Interferon Cytokine Res,2015,35(7):499-512.
[5] PANKRATZ S,BITTNER S,HERRMANN A M,et al.Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo[J].FASEB J,2014,28(8):3435-3445.
[6] DEVERGNE O,BIRKENBACH M,KIEFF E.Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin[J].Proc Natl Acad Sci U S A,1997,94(22):12041-12046.
[7] KOCHETKOVA I,GOLDEN S,HOLDERNESS K,et al.IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen Ⅱ-induced arthritis via the production of IL-10[J].J Immunol,2010,184(12):7144-7153.
[8] KUO J,NARDELLI D T,WARNER T F,et al.Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and infected mice[J].Clin Vaccine Immunol,2011,18(7):1125-1132.
[9] 孟博,谢而付,周春刚.类风湿关节炎患者血清IL-35的水平及其与疾病活动度的关系[J].临床检验杂志,2016,34(4):277-280.
[10] 粟深伟,陆进明,盛君,等.类风湿关节炎患者血清白介素-33、白介素-35表达及其临床意义[J].皖南医学院学报,2012,31(6):450-452.
[11] 刘丽.多发性硬化患者血清IL-33及IL-35水平的变化及其临床意义[D].郑州:郑州大学,2013.
[12] 高艺伟.格林-巴利综合征患者血清IL-17及IL-35水平的变化及其临床意义[D].郑州:郑州大学,2012.
[13] 郭敏.IL-35、IL-17在慢性荨麻疹患者血清中的表达及意义[D].太原:山西医科大学,2016.
[14] 寇晓丽.过敏性紫癜患者血清中IL-18、IL-33及IL-35的表达及意义[D].石家庄:河北医科大学,2014.
[15] MOLDAVER D M,BHARHANI M S,WATTIE J N,et al.Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35[J].Mucosal Immunol,2014,7(2):379-390.
[16] WHITEHEAD G S,WILSON R H,NAKANO K,et al.IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease[J].J Allergy Clin Immun,2012,129(1):207-215.e5.
[17] CHEN C,DENG Y,CHEN H,et al.Decreased concentration of IL-35 in plasma of patients with asthma and COPD[J].2014,32(3):211-217.
[18] 袁浩,周毅峰,杨明,等.小儿支原体肺炎患者外周血中IL-35与巨噬细胞、树突状细胞水平的相关性研究[J].中国卫生检验杂志,2016(24):3543-3545.
[19] WIRTZ S,BILLMEIER U,MCHEDLIDZE T,et al.Interleukin-35 mediates mucosal immune responses that protect against t-cell-dependent colitis[J].Gastroenterology,2011,141(5):1875-1886.
[20] 李艳梅.IL-35在炎症性肠病患者血清和肠黏膜组织中的表达[D].济南:山东大学,2015.
[21] 石银月,颜学兵,徐娟,等.慢性HBV感染者外周血中IL-35表达水平的检测及其意义[J].中华实验和临床感染病杂志(电子版),2012,6(3):33-36.
[22] HU Y,DONG C,YUE Y,et al.In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells[J].Arch Virol,2014,159(9):2411-2419.
[23] 张传峰,苑海涛.病毒性心肌炎患者血清IL17、IL35水平变化及意义[J].山东医药,2014(31):28-30.
[24] BARRERE J M,FRANCIS B,ERCILLA G,et al.Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA[J].Vox Sang,2010,68(1):15-18.
[25] 罗程,吉庆伟,林英忠,等.冠心病患者血浆IL-35水平的变化及意义[J].细胞与分子免疫学杂志,2013,29(7):759-760.
[26] 台适,周胜华,刘启明,等.冠心病患者血浆IL-35水平及临床意义的探讨[C].天津:中华医学会,2013.
[27] LIN Y,HUANG,LU Z,et al.Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases[J].PLoS One,2012,7(12):e52490.
[28] JIN P,REN H,SUN W,et al.Circulating IL-35 in pancreatic ductal adenocarcinoma patients[J].Human Immunology,2014,75(1):29-33.
[29] GU X,TIAN T,ZHANG B,et al.Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer[J].Tumour Biol,2015,36(4):2651-2656.
[30] TAO Q,PAN Y,WANG Y,et al.Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts[J].Int J Cancer,2015,137(10):2384-2393.
[31] LONG J,ZHANG X,WEN M,et al.IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells[J].Biochem Biophys Res Commun,2013,430(1):364-369. |
